XML 45 R34.htm IDEA: XBRL DOCUMENT
v3.25.3

REVENUES - Summary of Total Revenues (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended
--- | --- | ---
Sep. 30, 2025 | Sep. 30, 2024 | Sep. 30, 2025 | Sep. 30, 2024
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | $ 7,769 | $ 7,545 | $ 21,518 | $ 21,185
U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 5,281 | 5,450 | 15,000 | 15,024
Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 1,555 | 1,167 | 3,828 | 3,459
Rest of World |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 933 | 929 | 2,690 | 2,703
Total product sales |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 7,345 | 7,515 | 21,013 | 21,074
Total product sales | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 5,274 | 5,433 | 14,943 | 14,958
Total product sales | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 1,144 | 1,154 | 3,395 | 3,416
Total product sales | Rest of World |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 928 | 928 | 2,674 | 2,700
Total HIV |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 5,277 | 5,073 | 14,952 | 14,160
Total HIV | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 4,299 | 4,161 | 12,059 | 11,386
Total HIV | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 592 | 570 | 1,769 | 1,737
Total HIV | Rest of World |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 386 | 342 | 1,124 | 1,038
Biktarvy |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 3,686 | 3,472 | 10,366 | 9,649
Biktarvy | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 2,940 | 2,826 | 8,212 | 7,726
Biktarvy | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 427 | 375 | 1,231 | 1,110
Biktarvy | Rest of World |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 320 | 272 | 922 | 814
Descovy |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 701 | 586 | 1,939 | 1,496
Descovy | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 652 | 534 | 1,791 | 1,339
Descovy | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 23 | 24 | 67 | 75
Descovy | Rest of World |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 25 | 28 | 81 | 82
Genvoya |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 377 | 449 | 1,118 | 1,292
Genvoya | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 323 | 384 | 950 | 1,088
Genvoya | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 34 | 44 | 114 | 138
Genvoya | Rest of World |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 19 | 21 | 54 | 66
Odefsey |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 277 | 326 | 857 | 952
Odefsey | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 206 | 248 | 642 | 705
Odefsey | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 61 | 69 | 184 | 217
Odefsey | Rest of World |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 10 | 9 | 30 | 30
Symtuza - Revenue share |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 124 | 139 | 362 | 448
Symtuza - Revenue share | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 95 | 103 | 265 | 338
Symtuza - Revenue share | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 26 | 33 | 88 | 101
Symtuza - Revenue share | Rest of World |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 3 | 3 | 9 | 9
Other HIV |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 112 | 100 | 310 | 322
Other HIV | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 82 | 65 | 198 | 190
Other HIV | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 22 | 26 | 85 | 96
Other HIV | Rest of World |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 9 | 9 | 28 | 36
Total Liver Disease |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 819 | 733 | 2,372 | 2,302
Total Liver Disease | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 414 | 393 | 1,162 | 1,210
Total Liver Disease | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 158 | 132 | 496 | 411
Total Liver Disease | Rest of World |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 247 | 207 | 714 | 682
Sofosbuvir/Velpatasvir |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 309 | 385 | 996 | 1,266
Sofosbuvir/Velpatasvir | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 146 | 222 | 497 | 737
Sofosbuvir/Velpatasvir | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 65 | 67 | 227 | 230
Sofosbuvir/Velpatasvir | Rest of World |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 97 | 96 | 273 | 299
Vemlidy |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 280 | 232 | 783 | 699
Vemlidy | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 136 | 126 | 358 | 338
Vemlidy | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 12 | 11 | 36 | 33
Vemlidy | Rest of World |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 132 | 95 | 389 | 328
Other Liver Disease |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 231 | 116 | 593 | 337
Other Liver Disease | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 132 | 45 | 307 | 134
Other Liver Disease | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 81 | 54 | 233 | 148
Other Liver Disease | Rest of World |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 17 | 17 | 53 | 55
Veklury |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 277 | 692 | 700 | 1,461
Veklury | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 140 | 393 | 390 | 784
Veklury | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 43 | 81 | 84 | 204
Veklury | Rest of World |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 93 | 219 | 225 | 473
Total Oncology |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 788 | 816 | 2,395 | 2,446
Total Oncology | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 384 | 433 | 1,192 | 1,338
Total Oncology | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 275 | 291 | 821 | 828
Total Oncology | Rest of World |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 129 | 92 | 381 | 280
Total Cell Therapy |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 432 | 485 | 1,381 | 1,485
Total Cell Therapy | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 163 | 208 | 566 | 683
Total Cell Therapy | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 186 | 211 | 562 | 611
Total Cell Therapy | Rest of World |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 83 | 66 | 253 | 192
Tecartus |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 83 | 98 | 254 | 305
Tecartus | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 40 | 63 | 122 | 181
Tecartus | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 35 | 29 | 107 | 102
Tecartus | Rest of World |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 8 | 6 | 25 | 22
Yescarta |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 349 | 387 | 1,127 | 1,181
Yescarta | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 123 | 145 | 444 | 502
Yescarta | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 151 | 182 | 455 | 509
Yescarta | Rest of World |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 75 | 60 | 228 | 170
Trodelvy |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 357 | 332 | 1,013 | 960
Trodelvy | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 221 | 226 | 626 | 655
Trodelvy | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 89 | 80 | 259 | 217
Trodelvy | Rest of World |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 47 | 26 | 128 | 88
Total Other |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 184 | 201 | 594 | 705
Total Other | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 36 | 53 | 140 | 241
Total Other | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 76 | 80 | 225 | 236
Total Other | Rest of World |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 72 | 68 | 230 | 228
AmBisome |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 123 | 130 | 391 | 424
AmBisome | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 2 | 6 | 15 | 37
AmBisome | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 69 | 71 | 201 | 210
AmBisome | Rest of World |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 52 | 52 | 175 | 176
Other |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 61 | 71 | 204 | 281
Other | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 34 | 47 | 125 | 203
Other | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 7 | 8 | 23 | 26
Other | Rest of World |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 20 | 16 | 55 | 52
Royalty, contract and other revenues |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 424 | 30 | 505 | 111
Royalty, contract and other revenues | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 7 | 17 | 57 | 66
Royalty, contract and other revenues | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 411 | 13 | 433 | 43
Royalty, contract and other revenues | Rest of World |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | $ 5 | $ 1 | $ 16 | $ 2

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=gild_RestOfWorldMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsSymtuzaRevenueShareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsOtherHIVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_LiverDiseaseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_LiverDiseaseProductsSofosbuvirVelpatasvirMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_LiverDiseaseProductsVemlidyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_LiverDiseaseProductsOtherLiverDiseaseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_VekluryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OncologyProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_CellTherapyProductsTecartusMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsYescartaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_TrodelvyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |